Development of DNA vaccine against intracellular protozoa bored on ubiquitin-proteasome system

基于泛素-蛋白酶体系统的细胞内原虫DNA疫苗的研制

• 批准号: 16017276
• 负责人: HIMENO Kunisuke
• 金额: $ 9.6万
• 依托单位: KYUSHU UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research on Priority Areas
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16017276/
• 关键词: intracellular protozoa; DNA vaccine; gene gun; ubiquitin; ubiquitin-proteasome; CD84T cell; proteasome KO mice; proteasome inhibitor; 細胞内寄生原虫; ユビキチンプロテアソーム系; トキソプラズマ; SAG-1; ユビキチン融合遺伝子; PA28ノックアウトマウス

The intracellular protozoan Toxoplasma gondii (T.gondii) is a major opportunistic pathogen in the immunocompromized patient population worldwide. Among the vaccine candidates, the SAG1 protein is the best characterized. This 30-kDa protein is the major surface antigen of T gondii tachyzoites, is highly conserved in T gondii strains, inducing high antibody levels in humans, and is recognized by all the serum samples from infected subjects. CD8^+ T cells play an essential role in the protection against a highly virulent RH strain of T gondii. Some CD8^+ CTL epitopes included in the SAG1 had been defined. However, most vaccine trials including DNA vaccine have resulted in failure agaist the high virulent RH strain except against the cultured and attenuated strain. In the present study, we constructed the vaccine vector encoding ubiquitinated SAG1 which is expected to be processed by "ubiquitin-proteasome pathway" and then be led to MHC class I molecules, resulting in the activation of SAG1-specific CD8^+ T cells.Mice immunized with the chimeric DNA developed potent protective immunity against Toxoplasma mediated by SAG1-specific CD8^+T cells, while mice immunized with SAG1 gene alone did not. The enhanced immunity was dependent on the ubiquitination of SAG1 that enabled it to be efficiently processed by the proteasome pathway resulting in efficient induction of specific CD8^+T cells. The immunity was dependent on immunoproteasome LMP7 but independent on PA28a/b, a proteasome activator.

细胞内原生动物刚地弓形虫（弓形虫）是世界范围内免疫功能低下患者群体中的主要机会性病原体。在候选疫苗中，SAG1蛋白是最具特征的。这个30 kda的蛋白是弓形虫速殖子的主要表面抗原，在弓形虫菌株中高度保守，在人体内诱导高抗体水平，并被所有感染者的血清样本所识别。CD8^+ T细胞在抵抗高毒力RH弓形虫株中发挥重要作用。一些CD8^+ CTL表位已被定义在SAG1中。然而，大多数疫苗试验，包括DNA疫苗，除了针对培养和减毒菌株外，都导致对高毒力RH菌株的失败。在本研究中，我们构建了编码泛素化SAG1的疫苗载体，该载体有望通过“泛素-蛋白酶体途径”处理，然后被引导到MHC I类分子，从而激活SAG1特异性CD8^+ T细胞。用嵌合DNA免疫的小鼠对SAG1特异性CD8 +T细胞介导的弓形虫产生了有效的保护性免疫，而单独用SAG1基因免疫的小鼠则没有。增强的免疫力依赖于SAG1的泛素化，使其能够通过蛋白酶体途径有效地加工，从而有效地诱导特异性CD8^+T细胞。免疫依赖于免疫蛋白酶体LMP7，但不依赖于蛋白酶体激活剂PA28a/b。

项目成果

WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation pro-inflammatory cytokine production.

WSX-1 是通过调节促炎细胞因子的产生来抵抗克氏锥虫感染所必需的。

• 发表时间: 2003
• 期刊: Immunity 19(5)
• 作者: Toyooka;K.;et al.;Kaneko O;Yano K;Kaneko 0;Yano K;Arakawa T;Sawasaki T;Arakawa T;Sawasaki T;Arakawa T;Kaneko O;Rungruang T;Sattabongkot J;Li F;Li F;Ling IT;Tsuboi T;Li F;Kongkasuriyachai D;Win TT;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Zhang M. et al.;Hisaeda H. et al.;Okamoto M. et al.;Obata C. et al.;Onishi K. et al.;Yamanaka A. et al.;Zhang M. et al.;Li Y.et al.;Hisaeda H. et al.;Okamoto M. et al.;Obata C. et al.;Onishi K. et al.;Yamanaka A. et al.;Zhang M. et al.;Li Y.et al.;Hisaeda H. et al.;Onishi K. et al.;Yamanaka A. et al.;Hamano S. et al.;Seki YI. et al.;Katunuma N. et al.;Hisaeda H. et al.;Sakai T. et al.;Sakai T. et al.;Hamano S. et al.
• 通讯作者: Hamano S. et al.

Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant

• DOI: 10.1128/cdli.11.3.483-495.2004
• 发表时间: 2004-05-01
• 期刊: CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
• 作者: Okamoto, M;Oh-e, G;Ohkubo, S
• 通讯作者: Ohkubo, S

Toll-Like Receptor 4 Mediates the Antitumor Host Response Induced by a 55-Kilodalton Protein Isolated from Aeginetia indica L.,a Plant.

Toll 样受体 4 介导从 Aeginetia indica L. 植物中分离的 55 千道尔顿蛋白质诱导的抗肿瘤宿主反应。

• 发表时间: 2004
• 期刊: Clin Diagn Lab Immunol. 11・3
• 作者: Toyooka;K.;et al.;Kaneko O;Yano K;Kaneko 0;Yano K;Arakawa T;Sawasaki T;Arakawa T;Sawasaki T;Arakawa T;Kaneko O;Rungruang T;Sattabongkot J;Li F;Li F;Ling IT;Tsuboi T;Li F;Kongkasuriyachai D;Win TT;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Zhang M. et al.;Hisaeda H. et al.;Okamoto M. et al.
• 通讯作者: Okamoto M. et al.

Malaria vaccines that inhibit parasite spread by mosquito vectors

抑制蚊媒传播寄生虫的疟疾疫苗

• 发表时间: 2003
• 期刊: Recent Research Developments in Immunology 5
• 作者: Toyooka;K.;et al.;Kaneko O;Yano K;Kaneko 0;Yano K;Arakawa T;Sawasaki T;Arakawa T;Sawasaki T;Arakawa T;Kaneko O;Rungruang T;Sattabongkot J;Li F;Li F;Ling IT;Tsuboi T;Li F;Kongkasuriyachai D;Win TT;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Zhang M. et al.;Hisaeda H. et al.;Okamoto M. et al.;Obata C. et al.;Onishi K. et al.;Yamanaka A. et al.;Zhang M. et al.;Li Y.et al.;Hisaeda H. et al.;Okamoto M. et al.;Obata C. et al.;Onishi K. et al.;Yamanaka A. et al.;Zhang M. et al.;Li Y.et al.;Hisaeda H. et al.;Onishi K. et al.;Yamanaka A. et al.;Hamano S. et al.;Seki YI. et al.;Katunuma N. et al.;Hisaeda H. et al.
• 通讯作者: Hisaeda H. et al.

A novel DNA vaccine based on the ubiquitin-proteasome pathway targeting 'self' antigens expressed in melanoma/melanocyte

一种基于泛素-蛋白酶体途径的新型 DNA 疫苗，针对黑色素瘤/黑色素细胞中表达的“自身”抗原

• 发表时间: 2005
• 期刊: Gene Ther. 12
• 作者: Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Duan X.et al.;Ishii K. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Hisaeda H. et al.;Zhang M. et al.;Hisaeda H. et al.;Zhang M. et al.
• 通讯作者: Zhang M. et al.